Can Fite BiopharmaCANF -6.46%55 PS Ratio is 5.33 as of Jun. 27, 2026, which is 73% below its 10-year median of 19.98. GuruFocus rates CANF with a GF Score™ of 55/100 and a GF Value™ of $5.68 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 936 Biotechnology companies, Can Fite Biopharma ranks better than 60.79% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Can Fite Biopharma's share price is $2.75.
Can Fite Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.52. Hence, Can Fite Biopharma's PS Ratio for today is 5.33.
Good Sign:
Can Fite Biopharma Ltd stock PS Ratio (=7.01) is close to 5-year low of 6.47.
The historical rank and industry rank for Can Fite Biopharma's PS Ratio or its related term are showing as below:
CANF'
s PS Ratio Range Over the Past 10 Years
Min: 0.85 Med: 19.98 Max: 255.2
Current: 6
During the past 13 years, Can Fite Biopharma's highest PS Ratio was 255.20. The lowest was 0.85. And the median was 19.98.
CANF's PS Ratio is ranked better than 60.79% of 936
companies
in the Biotechnology industry
Industry Median: 9.165
vs CANF: 6.00
Can Fite Biopharma Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Can Fite Biopharma was -73.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -58.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -47.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -41.20% per year.
During the past 13 years, Can Fite Biopharma's highest 3-Year average Revenue per Share Growth Rate was 142.40% per year. The lowest was -74.90% per year. And the median was -49.40% per year.
Back to Basics: PS Ratio
Can Fite Biopharma (AMEX:CANF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Can Fite Biopharma PS Ratio Related Terms
Can Fite Biopharma PS Ratio Historical Data
* Premium members only.
The historical data trend for Can Fite Biopharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Can Fite Biopharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Can Fite Biopharma PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Can Fite Biopharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where Can Fite Biopharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Can Fite Biopharma's Share Price of today is $2.75.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Can Fite Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.52.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Can Fite Biopharma (CANF) has a PS Ratio of 5.33 as of Jun. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Can Fite Biopharma and its competitors. This is 73% below median its historical median of 19.98. Over the past decade, Can Fite Biopharma's PS Ratio has ranged from 0.85 to 255.20. According to the industry distribution chart, Can Fite Biopharma ranks #367 out of 936 companies in the Biotechnology industry, placing it in the top 39.2%.
Is Can Fite Biopharma's PS Ratio too high?
Can Fite Biopharma's current PS Ratio of 5.33 is 73% below median its 10-year median of 19.98. Over the past 10 years, this metric has ranged from a low of 0.85 to a high of 255.20. The Biotechnology industry median PS Ratio is 9.17. Can Fite Biopharma's value of 5.33 is 41.8% below this industry median. Based on the distribution chart, Can Fite Biopharma ranks #367 out of 936 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Can Fite Biopharma has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Can Fite Biopharma's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Can Fite Biopharma ranks #367 out of 936 companies for PS Ratio. This puts Can Fite Biopharma in the upper half of its industry. The industry median PS Ratio is 9.17. Can Fite Biopharma's value of 5.33 is 41.8% below this benchmark. Historically, Can Fite Biopharma's own PS Ratio has ranged from 0.85 to 255.20 over the past decade. While the company's 10-year median is 19.98 vs. the industry median of 9.17, Can Fite Biopharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.17, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Can Fite Biopharma's current PS Ratio of 5.33 is 41.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Can Fite Biopharma and its competitors. For the Biotechnology industry, the median PS Ratio is 9.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Can Fite Biopharma's current PS Ratio is 5.33, which is 73% below median its own 10-year median of 19.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Can Fite Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Can Fite Biopharma (CANF) is currently considered Possible Value Trap. The stock's GF Value™ is $5.68, compared to a current price of $2.75 — trading 51.6% below its estimated fair value. The current PS Ratio is 5.33, which is 73% below median its 10-year median of 19.98 and 41.8% below the Biotechnology industry median of 9.17. Can Fite Biopharma's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Can Fite Biopharma (CANF), the current PS Ratio is 5.33 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Can Fite Biopharma (CANF) Overvalued in 2026?
Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued.
The current stock price of $2.75 is trading 51.6% below its estimated GF Value™ of $5.68.
GuruFocus considers Can Fite Biopharma to be Possible Value Trap.
Key valuation signals for CANF:
PS Ratio: 5.33 (73% below median its 10-year median of 19.98)
GF Value™: $5.68 vs. price of $2.75 (51.6% below fair value)
Industry Position: 41.8% below the Biotechnology median (#367 of 936)
No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
55GF Score
Get the complete analysis for CANF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CANF has been successfully added to your 
